IPO Guru
Bajaj
Listed Mainboard

Concord Biotech IPO Review

Concord Biotech IPO has been reviewed by 7 analysts, and the overall consensus is Strong Apply — carrying a score of 100. Out of the 7 analysts who have covered this IPO, 7 recommend subscribing — reflecting a broadly positive view from the analyst community.

The issue is priced in the band of ₹705-741 per share, with a minimum application size of 20 shares (minimum investment of approximately ₹14,820 at the upper band). Subscription ran from 04 Aug 2023 to 08 Aug 2023. The issue size is ₹1,551 crore, entirely an offer for sale — the company receives none of the proceeds. As of now, the grey market premium (GMP) for Concord Biotech IPO is quoting at ₹67.67 (9%), which gives a preliminary sense of how the street is pricing the listing — though GMP is unofficial and can swing sharply before the listing date. Scroll down for the full analyst breakdown and analyst-wise verdicts.

Abhishek Vohera, Founder of IPO Guru Researched & reviewed by Abhishek Vohera, Founder, IPO Guru Last updated Figures sourced from the RHP, BSE & NSE

Analyst verdict & score

One score out of 100, aggregated from every analyst verdict tracked for this issue. How it's calculated

Sentiment score
100/ 100
Strong Apply 7 of 7 recommend subscribing
How analysts voted
Apply 7
Not rated 3

Higher consensus indicates broader analyst agreement.

Detailed review

A written summary will appear here once enough analyst reports are in. Until then, read the analyst-wise verdicts below.

Advertisement

Analyst reviews

Ordered by each analyst's track record over the past year; analysts still building one are listed last.

Latest IPO reviews

How analysts rated the most recent mainboard issues — and, where they have listed, how the call played out.

Frequently asked

Should I apply for Concord Biotech IPO?

The analyst consensus for Concord Biotech IPO tracked on this page is Strong Apply, with a score of 100/100. Out of 7 analysts who have reviewed this IPO, 7 recommend subscribing. IPO Guru does not make buy or sell recommendations. Read the individual analyst reports and consult a SEBI-registered advisor before investing.

What does the score of 100 mean for Concord Biotech IPO?

The score of 100 is an aggregate of all analyst ratings tracked for Concord Biotech IPO. A score in this range indicates strong analyst confidence — most analysts are recommending a subscribe. Read the individual analyst verdicts above for more context.

What was the actual listing price of Concord Biotech IPO?

Concord Biotech IPO listed on August 18, 2023 at ₹900.05, against the issue price of ₹741 — a gain of +21.46% (₹159.05 per share). View the full GMP history page for day-wise pre-listing trends.

What is the price band and lot size of Concord Biotech IPO?

Concord Biotech IPO was priced at ₹705-741 per share. The minimum lot size is 20 shares, making the minimum investment approximately ₹14,820 at the upper end of the price band. Subscription ran from 04 Aug 2023 to 08 Aug 2023.

Explore Concord Biotech IPO further

Analyst views are one input. Read them alongside the demand, the grey market and the filings before you decide.

Concord Biotech IPO review

A verdict is an opinion, not a guarantee.

IPO Guru collects analyst views, GMP, subscription and allotment for every Mainboard and SME issue. Weigh them together — and against the offer document — before you apply.

Join the WhatsApp channel Full IPO details

Disclaimer: Grey Market Premium (GMP) is for information purposes and is not a guarantee of listing price. Always consult your financial advisor before investing.

Consensus
Strong Apply
Score
100 / 100
Listed at
₹900.05
Full IPO details
Advertisement